- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01446289
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Leuven
-
Herestraat, Leuven, Belgien, 49-B-3000
- UZ Leuven
-
-
Tienen
-
Gasthuismolenstraat 31, Tienen, Belgien, 3300
- Regionaal Ziekenhuis Heilig Hart,
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H3N1
- University of British Columbia, Rm B3 25 B, 4500 Oak Street,
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Dalhousie University, IWK Health Centre, 5850/5980 University Avenue,
-
-
Quebec
-
Boulevard laurier, S-745, Quebec, Kanada, G1V 4G2
- Centre hospitalier universitaire de Quebec (CHUQ)- hospital CHUL, Centre de recherche en infectiologie, 2705,
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy pregnant women 18-40 years of age at 24-35 weeks of gestation at screening.
- Individuals who have given a written consent after the nature of the study has been explained according to local regulatory requirements.
- Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
- Individuals who will be available for all scheduled visits (ie, not planning to leave the area before the end of the study period).
Exclusion Criteria:
- Individuals who were unwilling and/or unable to give written informed consent to participate in the study.
- Individuals with a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.
Individuals with any known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from:
- receipt of immunosuppressive therapy within 30 days prior to enrollment (any systemic corticosteroid administered for more than 5 days, or in a daily dose > 15 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy).
- receipt of immunostimulants.
- receipt of parenteral immunoglobulin preparation, blood products, and /or plasma derivatives within 12 weeks prior to enrollment and for the full length of the study.
Note: Anti-D (Rho) Immunoglobulins (anti-RhD) given for Anti-D prophylaxis were to be allowed.
Individuals characterized as "high risk" pregnancies at investigator discretion, such as those who have:
- gestational diabetes
- preeclampsia/eclampsia
- women at risk of preterm labor (except positivity for vaginal GBS)
- History of previous pregnancy complications including delivery of preterm infant.
- History of still-birth, late abortions and children with congenital anomalies.
- Individuals who had received any other investigational agent or investigational intervention during the course of the study.
- Individuals with acute infection including oral temperature ≥ 38°C were to be temporarily excluded. They could be enrolled once the infection had resolved (as judged by investigator).
- HIV positive by history.
Individuals reporting any known or suspected serious acute, chronic or progressive disease (eg, any history of neoplasm, malignancy, including lymphoproliferative disorder, diabetes, cardiac disease, malnutrition, renal failure, autoimmune disease, HBV or HCV, blood disorders).
Note: Malignancies, highly likely to having been cured at the investigators discretion are allowed. (eg, no relapse since 5 years post last malignancy specific treatment).
- Individuals with bleeding diathesis, or any condition that might have been associated with a prolonged bleeding time.
- Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, might have interfered with the subject's ability to participate in the study (eg, who were not able to comprehend or to follow all required study procedures for the whole period of the study).
- Individuals with any progressive or severe neurologic disorder, seizure disorder, epilepsy or Guillain-Barré syndrome.
- Individuals with history or any illness that, in the opinion of the investigator, might have posed additional risk to subjects due to participation in the study.
- Individuals who were part of study personnel or close family members conducting this study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group B Streptococcus Trivalent Vaccine
Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
|
Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
|
Placebo-Komparator: Placebo
Pregnant women who received one injection of saline solution.
|
Pregnant women who received one injection of saline solution administered intramuscularly.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/Birth
Zeitfenster: Day of delivery/birth
|
GMCs of anti-Group B Streptococcus (GBS) capsular polysaccharide (CPS) antibodies against serotypes Ia, Ib and III in mothers and in infants at delivery/birth are presented.
|
Day of delivery/birth
|
Geometric Mean of the Ratios Between Infant Antibody Level (μg/mL) and Maternal Antibody Level (μg/mL) at Time of Delivery
Zeitfenster: Day of delivery/birth
|
The Geometric mean transfer ratio of anti-GBS CPS antibodies against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery.
|
Day of delivery/birth
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
GMCs (Enzyme-linked Immunosorbent Assay, ELISA) Antibodies Against Serotypes Ia, Ib and III in Maternal Subjects
Zeitfenster: Day 1, day 31 and day 91 post-delivery
|
GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in maternal subjects at study day 1, study day 31 and at day 91 post-partum after one administration of GBS vaccine or placebo are reported.
|
Day 1, day 31 and day 91 post-delivery
|
Geometric Mean Ratios (GMRs) of Antibody GMCs (ELISA) in Maternal Subjects
Zeitfenster: Day 31, day of delivery, day 91 post-delivery
|
GMRs of GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III, in maternal subjects at study day 31, at delivery and at day 91 post-partum versus day 1 (baseline) after one administration of GBS vaccine or placebo are reported.
|
Day 31, day of delivery, day 91 post-delivery
|
GMC (ELISA) of Anti-GBS CPS Antibodies in Infants
Zeitfenster: Day of birth and day 91 after birth
|
GMC (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in infants at birth and at 3 months of age are reported.
|
Day of birth and day 91 after birth
|
GMRs of Anti-GBS CPS Antibody GMCs (ELISA) in Infants at 3 Months of Age Versus GMCs at Birth
Zeitfenster: Day 91 after birth
|
GMRs of anti-GBS CPS antibody GMCs (ELISA) against serotypes Ia, Ib and III in infants at 3 months of age (day 91 after birth) versus GMCs at birth are reported.
|
Day 91 after birth
|
Percentages of Infant Subjects Showing Anti-diphtheria Antibodies GMCs (ELISA) Over 0.1 IU/mL at 1 Month After the Last Routine Infant Immunization
Zeitfenster: 1 month after the last routine infant immunization
|
Percentages of infant subjects showing anti-diphtheria antibodies GMCs (ELISA) over 0.1 IU/mL in sera collected at 1 month after the last routine infant immunization (ie, either 5 months or 7 months after birth, depending on the vaccination schedule) are reported.
|
1 month after the last routine infant immunization
|
Percentage of Maternal Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)
Zeitfenster: From day 1 to 7 after vaccination
|
Percentage of maternal subjects reporting solicited local and systemic AEs and other indicators of reactogenicity from day 1 to 7 after vaccination are reported.
|
From day 1 to 7 after vaccination
|
Percentage of Maternal Subjects Reporting Unsolicited AEs and Serious Adverse Events (SAEs)
Zeitfenster: All AEs were recorded until delivery, after delivery all AEs requiring a non-routine physician's visit and AEs leading to withdrawal from the study. SAEs were collected for the duration of the trial.
|
Percentage of maternal subjects reporting unsolicited AEs, SAEs, AEs requiring a non-routine physician's visit, AEs leading to withdrawal are reported.
|
All AEs were recorded until delivery, after delivery all AEs requiring a non-routine physician's visit and AEs leading to withdrawal from the study. SAEs were collected for the duration of the trial.
|
Percentages of Infants Reporting SAEs
Zeitfenster: From birth until study termination
|
Percentages of infants born from women who received either one injection of the study vaccine or placebo, reporting SAEs from birth until study termination are reported.
|
From birth until study termination
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Gilbert Donders, Prof., Regional Hospital Heilig Hart, Tienen, Belgium
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Fabbrini M, Rigat F, Tuscano G, Chiarot E, Donders G, Devlieger R, Filippini S, Frigimelica E, Forte P, Wittke F, Halperin SA, Slobod K, Grandi G, Margarit I. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. J Infect. 2018 May;76(5):449-456. doi: 10.1016/j.jinf.2018.01.006. Epub 2018 Jan 31.
- Donders GG, Halperin SA, Devlieger R, Baker S, Forte P, Wittke F, Slobod KS, Dull PM. Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial. Obstet Gynecol. 2016 Feb;127(2):213-21. doi: 10.1097/AOG.0000000000001190.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- V98_04
- 2010-020840-36
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bakterielle Infektion
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Group B Streptococcus Trivalent Vaccine
-
Novartis VaccinesAbgeschlossen
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenGrippe | Myxovirus-Infektion | Orthomyxovirus-InfektionVereinigte Staaten
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenGrippe | Orthomyxoviridae-Infektion | Myxovirus-InfektionVereinigte Staaten, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenGrippeVereinigte Staaten, Puerto Rico
-
Emory UniversityNational Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)AbgeschlossenNeoplasma von PlasmazellenVereinigte Staaten
-
Roswell Park Cancer InstituteAbgeschlossenAkute myeloische Leukämie | Myelodysplastisches SyndromVereinigte Staaten
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossen
-
BLIS Technologies LimitedRekrutierung
-
University of Maryland, BaltimoreBill and Melinda Gates FoundationAbgeschlossen
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AbgeschlossenGliom | Astrozytom | OligodendrogliomVereinigte Staaten